FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377220810> ?p ?o ?g. }

• W4377220810 endingPage "988" @default.
• W4377220810 startingPage "981" @default.
• W4377220810 abstract "Abstract Aims Patients with heart failure experience a high burden of symptoms and physical limitations, and poor quality of life. Dapagliflozin reduces heart failure hospitalization and cardiovascular death in patients with reduced, mildly reduced, and preserved ejection fractions. We examined the effects of dapagliflozin on health status, measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), across the full spectrum of left ventricular ejection fraction (LVEF). Methods and results Participant‐level data were pooled from the DAPA‐HF and DELIVER trials. Both trials were randomized, global, double‐blind, placebo‐controlled trials of patients with symptomatic heart failure and elevated natriuretic peptides. DAPA‐HF and DELIVER included patients with LVEF ≤40% and LVEF >40%, respectively. KCCQ was evaluated at randomization and at 4 and 8 months post‐randomization; the effect of dapagliflozin versus placebo on KCCQ total symptom score (TSS) was a pre‐specified secondary outcome in both trials. Interaction testing was performed to assess potential heterogeneity in the effects of dapagliflozin versus placebo on KCCQ‐TSS, clinical summary score (CSS), overall summary score (OSS), and physical limitation score (PLS), by continuous LVEF using restricted cubic splines. Responder analyses examining the proportion of patients with meaningful deterioration (≥5 point decline) and meaningful improvements (≥5 point increase) in KCCQ‐TSS was assessed across LVEF categories. Of 11 007 randomized participants, 10 238 (93%) had full data on KCCQ‐TSS at randomization. Benefits of dapagliflozin versus placebo on KCCQ‐TSS, ‐CSS, ‐OSS, ‐PLS, at 8 months were consistent across the full range of LVEF ( p interaction = 0.19, 0.10, 0.12, 0.10, respectively). In responder analyses, fewer dapagliflozin‐ versus placebo‐treated patients had clinically meaningful deteriorations in KCCQ‐TSS (overall: 21% vs. 23%; LVEF ≤40%: 21% vs. 29%; LVEF 41–60%: 21% vs. 26%; LVEF >60%: 22% vs. 27%). A greater proportion of patients randomized to dapagliflozin experienced at least small improvements in KCCQ‐TSS (overall: 50% vs. 45%; LVEF ≤40%: 48% vs. 41%; LVEF 41–60%: 51% vs. 49%; LVEF >60%: 53% vs. 45%). The effects of dapagliflozin versus placebo on clinically meaningful deteriorations and improvements in health status by KCCQ‐TSS were consistent across the full spectrum of LVEF assessed continuously ( p interaction = 0.20 and 0.64, respectively). Across the LVEF spectrum, the number needed to treat to affect ≥5 point improvement in health status assessed by KCCQ‐TSS was 20. Health status declines preceding a HF hospitalization by ∼10 points were observed in both trials, evident up to 3 months prior to hospitalization. Conclusions In participant‐level pooled analyses of DAPA‐HF and DELIVER, dapagliflozin improved all key domains of health status across the full range of LVEF. Clinically meaningful improvements in health status were also observed consistently across LVEF, including in those with LVEF >60%. Clinical Trial Registration: NCT03036124 and NCT03619213." @default.
• W4377220810 created "2023-05-23" @default.
• W4377220810 creator A5005006476 @default.
• W4377220810 creator A5005215114 @default.
• W4377220810 creator A5010456790 @default.
• W4377220810 creator A5012551917 @default.
• W4377220810 creator A5012849300 @default.
• W4377220810 creator A5018432247 @default.
• W4377220810 creator A5031658795 @default.
• W4377220810 creator A5034537174 @default.
• W4377220810 creator A5043224002 @default.
• W4377220810 creator A5044740469 @default.
• W4377220810 creator A5048450888 @default.
• W4377220810 creator A5052533254 @default.
• W4377220810 creator A5054830306 @default.
• W4377220810 creator A5061823235 @default.
• W4377220810 creator A5061881316 @default.
• W4377220810 creator A5066566704 @default.
• W4377220810 creator A5070626837 @default.
• W4377220810 creator A5080491086 @default.
• W4377220810 date "2023-06-07" @default.
• W4377220810 modified "2023-10-03" @default.
• W4377220810 title "Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the <scp>DAPA‐HF</scp> and <scp>DELIVER</scp> trials" @default.
• W4377220810 cites W2547126679 @default.
• W4377220810 cites W2974260792 @default.
• W4377220810 cites W2989060738 @default.
• W4377220810 cites W3011957437 @default.
• W4377220810 cites W3014670222 @default.
• W4377220810 cites W3132267344 @default.
• W4377220810 cites W4200116290 @default.
• W4377220810 cites W4200586754 @default.
• W4377220810 cites W4225396975 @default.
• W4377220810 cites W4226356934 @default.
• W4377220810 cites W4281261528 @default.
• W4377220810 cites W4293354639 @default.
• W4377220810 cites W4308741991 @default.
• W4377220810 cites W4311441791 @default.
• W4377220810 cites W4377093422 @default.
• W4377220810 doi "https://doi.org/10.1002/ejhf.2909" @default.
• W4377220810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37211977" @default.
• W4377220810 hasPublicationYear "2023" @default.
• W4377220810 type Work @default.
• W4377220810 citedByCount "2" @default.
• W4377220810 countsByYear W43772208102023 @default.
• W4377220810 crossrefType "journal-article" @default.
• W4377220810 hasAuthorship W4377220810A5005006476 @default.
• W4377220810 hasAuthorship W4377220810A5005215114 @default.
• W4377220810 hasAuthorship W4377220810A5010456790 @default.
• W4377220810 hasAuthorship W4377220810A5012551917 @default.
• W4377220810 hasAuthorship W4377220810A5012849300 @default.
• W4377220810 hasAuthorship W4377220810A5018432247 @default.
• W4377220810 hasAuthorship W4377220810A5031658795 @default.
• W4377220810 hasAuthorship W4377220810A5034537174 @default.
• W4377220810 hasAuthorship W4377220810A5043224002 @default.
• W4377220810 hasAuthorship W4377220810A5044740469 @default.
• W4377220810 hasAuthorship W4377220810A5048450888 @default.
• W4377220810 hasAuthorship W4377220810A5052533254 @default.
• W4377220810 hasAuthorship W4377220810A5054830306 @default.
• W4377220810 hasAuthorship W4377220810A5061823235 @default.
• W4377220810 hasAuthorship W4377220810A5061881316 @default.
• W4377220810 hasAuthorship W4377220810A5066566704 @default.
• W4377220810 hasAuthorship W4377220810A5070626837 @default.
• W4377220810 hasAuthorship W4377220810A5080491086 @default.
• W4377220810 hasBestOaLocation W43772208101 @default.
• W4377220810 hasConcept C126322002 @default.
• W4377220810 hasConcept C134018914 @default.
• W4377220810 hasConcept C142724271 @default.
• W4377220810 hasConcept C168563851 @default.
• W4377220810 hasConcept C1862650 @default.
• W4377220810 hasConcept C203092338 @default.
• W4377220810 hasConcept C204243189 @default.
• W4377220810 hasConcept C204787440 @default.
• W4377220810 hasConcept C27081682 @default.
• W4377220810 hasConcept C2777180221 @default.
• W4377220810 hasConcept C2777422806 @default.
• W4377220810 hasConcept C2778198053 @default.
• W4377220810 hasConcept C535046627 @default.
• W4377220810 hasConcept C555293320 @default.
• W4377220810 hasConcept C71924100 @default.
• W4377220810 hasConcept C78085059 @default.
• W4377220810 hasConceptScore W4377220810C126322002 @default.
• W4377220810 hasConceptScore W4377220810C134018914 @default.
• W4377220810 hasConceptScore W4377220810C142724271 @default.
• W4377220810 hasConceptScore W4377220810C168563851 @default.
• W4377220810 hasConceptScore W4377220810C1862650 @default.
• W4377220810 hasConceptScore W4377220810C203092338 @default.
• W4377220810 hasConceptScore W4377220810C204243189 @default.
• W4377220810 hasConceptScore W4377220810C204787440 @default.
• W4377220810 hasConceptScore W4377220810C27081682 @default.
• W4377220810 hasConceptScore W4377220810C2777180221 @default.
• W4377220810 hasConceptScore W4377220810C2777422806 @default.
• W4377220810 hasConceptScore W4377220810C2778198053 @default.
• W4377220810 hasConceptScore W4377220810C535046627 @default.
• W4377220810 hasConceptScore W4377220810C555293320 @default.
• W4377220810 hasConceptScore W4377220810C71924100 @default.
• W4377220810 hasConceptScore W4377220810C78085059 @default.
• W4377220810 hasFunder F4320307770 @default.
• W4377220810 hasIssue "7" @default.

• next